EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Analyst Earnings Estimates
NASDAQ:EPRX - Nasdaq - CA29842P1053 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A -68.64% | N/A 195.79% | N/A 190.18% | N/A 75.89% | N/A 50.86% | |||||||||
| EBITDA YoY % growth | -4.64M | -11.75M -153.23% | -5.99M 49.02% | -2.27M 62.10% | -18.12M -698.24% | -22.77M -25.66% | -27.33M -20.03% | -25.32M 7.36% | N/A -20.85% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.73M | -11.88M -151.16% | -6.19M 47.90% | -2.39M 61.39% | -18.23M -662.76% | -22.96M -25.95% | -27.443M -19.53% | -25.434M 7.32% | N/A -28.44% | N/A 45.61% | N/A 135.58% | N/A -1,141.17% | N/A 84.94% | N/A 1,490.09% | N/A 120.61% | N/A 51.70% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 34.44% | -1.22 -1.36% | -1.03 15.74% | N/A 5.38% | N/A 63.00% | N/A 106.35% | N/A -4,642.86% | N/A 80.14% | N/A 1,108.36% | N/A 66.23% | N/A 51.78% |
All data in USD
| Q2 / 25 | Q3 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.25 -9.14% | -0.26 -11.07% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -9.421M -52.82% | -9.548M -64.68% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.30 -6.36% | -0.24 | -0.06 | -23.87% |
| Q4 2024 Q2Q % growth | -0.28 26.32% | -0.16 | -0.12 | -80.04% |
| Q3 2024 Q2Q % growth | -0.23 7.20% | -0.27 | 0.03 | 12.99% |
| Q2 2024 Q2Q % growth | -0.23 35.28% | -0.24 | 0.00 | 2.06% |
| Q1 2024 Q2Q % growth | -0.28 -23.04% | -0.35 | 0.06 | 18.21% |
| Q4 2023 Q2Q % growth | -0.38 7.32% | -0.24 | -0.14 | -55.23% |
| Q3 2023 Q2Q % growth | -0.25 | -0.33 | 0.08 | 23.41% |
| Q2 2023 Q2Q % growth | -0.36 | -0.37 | 0.01 | 1.96% |
| Q1 2023 Q2Q % growth | -0.23 | -0.37 | 0.14 | 37.36% |
| Q4 2022 Q2Q % growth | -0.41 -51.85% | -0.44 | 0.03 | 6.52% |
| Q4 2021 Q2Q % growth | -0.27 | -0.43 | 0.16 | 36.97% |
| Q2 2021 Q2Q % growth | -0.38 | -0.56 | 0.18 | 31.64% |
| Q1 2021 Q2Q % growth | -0.86 | -0.14 | -0.72 | -524.55% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 6.02% | -24.65% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |